Overview

This trial is active, not recruiting.

Condition liver cancer
Treatment hsp90
Sponsor Protgen Ltd
Start date October 2012
End date December 2014
Trial size 1100 participants
Trial identifier NCT02324127, hsp90a2011-05

Summary

Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose diagnostic
Arm
(Experimental)
Detect plasma Hsp90α concentration of liver cancer patients
hsp90 biomarker
Detect plasma Hsp90α concentration of lung cancer patients

Primary Outcomes

Measure
Hsp90α Concentration of plasma
time frame: 4 months

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Liver cancer patients - Healthy volunteers, - Benign liver diseases patients Exclusion Criteria: - Patients who Previously accepted radiotherapy

Additional Information

Official title Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Principal investigator Shusen Zhen, MD
Description Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.
Trial information was received from ClinicalTrials.gov and was last updated in December 2014.
Information provided to ClinicalTrials.gov by Protgen Ltd.